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Abstract 
Redox adaptation plays an important role in cancer cells drug resistance. The antioxidant 
response is principally mediated by the transcription factor Nrf2, that induces the transcriptional 
activation of several genes involved in GSH synthesis, chemoresistance, and cytoprotection. 
YAP is emerging as a key mediator of chemoresistance in a variety of cancers, but its role in 
controlling the antioxidant status of the cells is yet elusive. Here, we show that impairing YAP 
protein expression reduced GSH content and Nrf2 protein and mRNA expression in bladder 
cancer cells. Moreover, in YAP- knockdown cells the expression of FOXM1, a transcription 
factor involved in Nrf2 transcription, was down-regulated and the silencing of FOXM1 reduced 
Nrf2 expression. On the other hand, the silencing of Nrf2, as well as the depletion of GSH by 
BSO treatment, inhibited YAP expression, suggesting that cross-talk exists between YAP and 
Nrf2 proteins. Importantly, we found that silencing either YAP or Nrf2 enhanced sensitivity of 
bladder cancer cells to cytotoxic agents and reduced their migration. Furthermore, the inhibition 
of both YAP and Nrf2 expressions significantly increased cytotoxic drug sensitivity and 
synergistically reduced the migration of chemoresistant bladder cancer cells. These findings 
provide a rationale for targeting these transcriptional regulators in patients with chemoresistant 
bladder cancer, expressing high YAP and bearing a proficient antioxidant system. 
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Introduction 
Redox status is a well-recognized actor in the adaptation of cancer cells to therapy [1]. Several 
types of cancer cells display a large amount of reactive oxygen species (ROS), due to an 
aberrant metabolism, mitochondrial dysfunction or activation of oncogenes [2]. This 
characteristic makes cancer cells more vulnerable to damage by further ROS production induced 
by cytotoxic therapeutic agents, such as cisplatin or doxorubicin, which trigger oxidative stress 
by binding to cytoplasmic nucleophilic species, including glutathione (GSH), and other 
cysteine-rich proteins, and induce cancer cell senescence and death [3]. However, some cancer 
cells, in particular those in advanced stages of disease, become highly adapted to intrinsic or 
drug-induced oxidative stress by up-regulating their GSH antioxidant system [3]. The 
transcription factor Nrf2 (NF-E2-related factor 2) is the master regulator of antioxidant and 
cytoprotective systems. Under physiological conditions, Nrf2 localizes in the cytoplasm where 
it is bound by Keap1 (Kelch-like ECH-associated protein 1). Keap1 forms a complex with Cul3 
and Rbx1, and this E3 ubiquitin ligase complex is able to bind and ubiquitinate Nrf2, resulting 
in Nrf2 proteasomal degradation [4]. Cellular oxidative stress triggers the oxidation of certain 
cysteine residues of Keap1, resulting in a conformational change of the Keap1–Nrf2 complex 
which prevents Nrf2 ubiquitination [4]. The stabilized Nrf2 accumulates in nuclei, 
heterodimerizes with small Maf proteins and activates target genes for cytoprotection through 
the antioxidant response element (ARE)/electrophile response element (EpRE) [5]. A Nrf2 role 
in chemoresistance has been demonstrated in diverse type of cancers, including cisplatin-
resistant bladder cancers [6-8]. 
Among the several genes involved in chemoresistance, increasing evidence has demonstrated 
the involvement of Yes-associated protein (YAP) in drug resistance of diverse types of cancers. 
YAP is a key component of the Hippo tumor-suppressor pathway [9], and Hippo pathway-
mediated YAP phosphorylation on Ser127 mainly leads to its cytoplasmic sequestration or 
ubiquitination and degradation [10]. Conversely, non-phosphorylated YAP translocates into the 
nucleus where it binds to transcription factors (mainly from TEAD family), triggering the 
expression of several genes involved in organ size control, cell proliferation and survival [11]. 
Indeed, inhibition of YAP expression results in reduced cell proliferation and enhanced cell 
death through modulation of downstream transcriptional targets [12].. YAP expression and 
nuclear localization strongly correlate with poor patient outcome and the progression of several 
tumors, including bladder cancer [12-15]. Recently, we demonstrated that constitutive 
expression and activation of YAP inversely correlated with “in vitro” and “in vivo” cisplatin 
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sensitivity of urothelial cell carcinoma cells [16]. YAP overexpression protects, while YAP 
knockdown sensitizes cancer cells to chemotherapy and radiation effects via increased 
accumulation of DNA damage and apoptosis [16]. Through the usage of an alternative 
transcription factor (FoxO1), YAP has also been linked to antioxidant balance maintenance in 
cardiomyocytes: YAP stimulation prevents, whereas YAP down-regulation promotes oxidative 
stress-induced cell death [17]. YAP binding to the transcription factor FoxO1 could form a 
functional complex on the promoters of antioxidant genes such as catalase and MnSOD, 
stimulating their transcription [17].  Recently, also the interaction with Pitx2 has been proposed 
as a mechanism for the YAP inducing antioxidant response in cardiomyocytes [18]. 
Interestingly, in this model, YAP cooperated with Nrf2 to sustain the antioxidant response, 
suggesting a functional crosstalk between the two pathways. Moreover, YAP expression is 
regulated, among the others, by a redox-dependent transcription factor: GABP, an Ets family 
member. Indeed, acetaminophen-induced GSH depletion inhibits GABP transcriptional activity 
and depletes YAP [19]. These data reiterate that a positive feedback loop between YAP and 
Nrf2 antioxidant system could exist. Indeed, the increase in antioxidant defenses could induce 
YAP expression, which in turn could promote the synthesis of antioxidant genes. Although a 
direct link between YAP and Nrf2 expression has not yet been proven, it can be argued by 
considering the regulation of forkhead box M1 (FOXM1) expression. This transcription factor is 
associated with a variety of aggressive solid carcinomas, including bladder cancer [20], and it is 
involved in the regulation of several genes, including Nrf2 [21]. It has been recently reported 
that YAP/TEAD regulates FOXM1 expression [22], thus, through this pathway YAP could 
affect Nrf2 expression.  
Although the role of Nrf2 and YAP in chemoresistance and in maintenance of the antioxidant 
cellular level has been demonstrated, no data are available in regards to a possible crosstalk 
between these two pathways in chemoresistant cancer cells which display high antioxidant 
level. In this study, we report that induction of cisplatin resistance in bladder cancer cells can 
affect the expression and function of Nrf2 and YAP and that the inhibition of YAP expression 
can interfere with the expression of Nrf2 and vice-versa, rescuing the sensitivity to 
chemotherapy. 
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Materials and methods 
 
Cells and culture conditions  
253J and 253J B-V cell lines were kindly provided by Dr Colin Dinney (MD Anderson Cancer 
Center). Human UCC cell line T24 was purchased from ATCC (Manassas, VA, USA). 
These cells were cultured in RPMI 1640, supplemented with 10% FBS, 100 units per ml penicillin 
and 100μg/ml streptomycin in a 5% CO 2, 37°C incubator.  
 
Induction of cisplatin resistance  
Resistance to cisplatin (CDDP) was induced by exposure of 253J and 253J B-V cells to 
progressively higher concentrations of CDDP (0.5-0.8-1-1.3-1.5 μg / ml). CDDP resistant cell lines 
were generated in Dr. Pili’s laboratory. Each concentration was maintained for at least 6 weeks and 
the viability of the resistant phenotype was verified. After this period, the cells remained for at least 
one month in the absence of drug; when a recovery of proliferation was observed, the drug 
concentration was increased to the higher dose. The induction of resistance to the highest drug 
concentration required a year. The acquired resistance was analyzed by MTT and colony forming 
assays.  
 
MTT assay 
The toxic effect of CDDP was determined through the 3-(4,5-dimethyl thiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. This is a colorimetric assay used to determine the level 
of metabolic activity in cells able to reduce the yellow tetrazolium dye MTT to purple formazan 
crystals. The amount of formazan produced an indication of the mitochondrial integrity and activity, 
which, in turn, may be interpreted as a measure of both cell viability and cell proliferation [23]. 
MTT analysis was performed in 96-well plates. Cells were seeded (800–1500 cells/well) in 200 μl 
of serum-supplemented medium and treated with different CDDP concentrations. Untreated cells 
were used as control. After this period, the drug was removed and MTT assay was performed. MTT 
was added to control and treated cells to a final concentration of 0.5 mg/ml (Sigma–Aldrich) for 2 
hours. The medium was then removed, and the cells were lysed with 100 μl of DMSO. Absorbance 
was recorded at 530 nm by a 96-well-plate ELISA reader.  
 
Crystal violet assay 
The viability of cells after CDDP treatment was detected through the staining with crystal violet 
dye, which binds to proteins and DNA. The amount of crystal violet staining depends on the 
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amount of adherent cells, where cells that undergo cell death lose their adherence and are 
subsequently lost from the cell population, reducing the amount of crystal violet staining in the well 
[24]. The crystal violet assay was determined as described by Feoktistova et al (2016) [24]. 
 
Colony-forming assay 
Cells were trypsinized, washed in 1×PBS, and seeded (500 cells/well) into a six-well plate and left 
overnight to attach. After 24 h, the cells were treated with the compounds and the medium was 
changed after 72 h. Cells were cultured for 9–11 days and subsequently fixed and stained with a 
solution of 90% crystal violet (Sigma–Aldrich), 10% methanol. The colonies were then 
photographed and counted with a Gel Doc equipment (Bio-Rad Laboratories). 
 
Analysis of GSH and GSSG contents 
GSH and GSSG contents were determined by the Owens and Belcher method [25] by using 2 x106 
cells for each condition and reported as a GSH/GSSG ratio. 
 
Lysate preparation and western blot analysis 
Cells were seeded in75-cm2 flasks and treated as indicated. Subsequently, the cells were harvested, 
washed once in ice-cold 1×PBS; resuspended in a lysis buffer composed of 20 mM Tris–HCl, pH 
7.4, 150 mM NaCl, 5 mM EDTA, 1% v/v Triton X-100, phosphatase (Sigma–Aldrich P2850), and 
protease (Sigma–Aldrich P8340) inhibitor cocktails; and incubated for 15 min at 4 °C. Samples 
were centrifuged at 10,000 rpm for 15 min at 4 °C, the supernatants were collected, and the protein 
concentration was determined using a commercially available kit (Bio-Rad Laboratories). Western 
blot analysis was performed using home-made 9.3% SDS–polyacrylamide gels or 5–15% gradient 
SDS–polyacrylamide precast gels (Bio-Rad Laboratories). Twenty to 40μg of proteins was mixed 
with 20μl of Laemmli sample buffer (Bio-Rad Laboratories 161-0737) containing 10% 2-
mercaptoethanol, boiled for5 min, and loaded onto the gels. The run was performed at the constant 
voltage of 100 V. The proteins were then transferred onto a nitrocellulose membrane with a semidry 
transfer apparatus (Biometra). The membranes were subsequently blocked for 1 h with 5% nonfat 
dry milk dissolved in TBS–Tween 20, incubated overnight at 4 °C with primary antibodies, washed 
three times with TBS–Tween 20, and incubated with HRP-conjugated secondary antibodies for 1 h 
at room temperature. Antibodies used were as follows: PARP (#9542), Asp214 cleaved PARP 
(#9541) glyceraldehyde 3 phosphate dehydrogenase (GAPDH) (#5174) (Cell Signaling, Boston, 
MA, USA); β-actin (sc-47778), YAP (sc15407), Nrf2 (sc 722), Keap-1 (sc33569), FOXM1 (sc 
271746) (Santa Cruz, Dallas, TX, USA); α-tubulin (04-1117, Millipore, Billerica, MA, USA); 
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thioredoxin (H00007295-M01) (Novus Biologicals, Milano, Italy); glutathione-S-transferase A4 
(SAB1401164) (Sigma–Aldrich). The detection of the bands was carried out after reaction with 
chemiluminescence reagents (PerkinElmer NEL105001EA) through film (Santa Cruz 
Biotechnology sc-201697) autoradiography. 
 
Immunofluorescence  
Cells (5x104) were plated into the channels of a µ–Slide VI0.4 (Ibidi, Giemme Snc, Milano, Italy). 
After treatments, cells were fixed for 15 min in 4% paraformaldehyde and permeabilized with 1% 
Triton X-100 for 30 min at room temperature and washed with PBS. Then, the slides were 
incubated with 1% BSA in 1x PBS for 30 min at room temperature, after which they were incubated 
for 1 h at room temperature with the primary monoclonal antibody against YAP (D8H1X, Cell 
Signaling, Boston, MA, USA) or Nrf2 (D179C, Cell Signaling, Boston, MA, USA) in 1% BSA 
dissolved in PBS. The cells were subsequently washed, incubated for 1 h at room temperature with 
the secondary FITC-conjugated antibody (1:100 in 0.1%BSA in 1x PBS). After washing with PBS, 
the cells were analyzed under a fluorescence microscope (Axiovert 35; Carl Zeiss MicroImaging 
GmbH, Jena, Germany). 
 
RNA interference  
Expression arrest pGIPZ lentiviral vector encoding non-silencing control shRNA or YAP1 shRNAs 
(V2LHS_65508 and V2LHS_65509, Thermo Scientific Open Biosystems, Waltham, MA, USA) 
were provided as described before [16]. Virus supernatant was applied with 8μg/ml polybrene on 
60–70% confluent cells and non-infected cells were eliminated through puromycin selection. In 
siRNA experiments, 2 × 104 253J C-r cells and T24 cells were seeded in 12-well plates in medium 
containing serum and antibiotics and transfected with 50 nM Nrf2-specific siRNA (SI 03246950; 
Qiagen) or FOXM1 specific RNA (sc-43769, Santa Cruz Biotechnology), using the HiPerfect 
transfection reagent (Qiagen) according to the manufacturer's instructions.  
 
BSO treatment 
253J C-r cells and T24 cells were seeded in 12-well plates in medium containing serum and 
antibiotics and treated with 100 or 200µM Buthionine-sulfoximine (BSO) (Sigma–Aldrich) for 24, 
48 and 72 hours. 
 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
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For reverse transcription, 1 μg of cells total RNA, 25 mM random hexamers and 100 U of Reverse 
Transcriptase (Thermo Fisher Scientific, USA) were used. Gene expression levels were measured 
by quantitative real time PCR (qRT-PCR) in an iCycler (Bio-Rad Laboratories, USA). Abelson 
(Abl) gene was utilized as housekeeping controls. The following TaqMan® Gene Expression Assay 
(Thermo Fisher Scientific, USA) were used: Hs00975960_m1 for Nrf2 gene; Hs00371735_m1, Life 
Technologies for YAP gene and Hs00245445_m1 for Abl gene,g respectively. For each PCR 
reaction, 50 ng of cDNA was added to PCR reaction mix containing 1x TaqMan Universal PCR 
Master Mix (Thermo Fisher Scientific, USA), 1x TaqMan® Gene Expression Assay (Thermo 
Fisher Scientific, USA) and distilled water to a final volume of 10 ul. All analyses were carried out 
in duplicate; results showing a discrepancy greater than one cycle threshold in one of the wells were 
excluded. The results were analyzed using the ΔΔCt method [26].  
 
Apoptosis 
Adherent and nonadherent cells where harvested, washed in 1 × PBS, and subsequently 
resuspended in annexin V binding buffer (556454; BD Pharmingen) supplemented with 1:100 
APC-conjugated annexin V (550474; BD Pharmingen) and 1 μg/ml propidium iodide (Sigma–
Aldrich). Cells were analyzed by a FACSCalibur cytometer (Becton Dickinson). 
 
Wound Healing Assay 
In the scratch assay, after starvation for 18–24 h in serum-free medium, cells were plated onto six-
well plates (106 cell/well) and grown to confluence. Cell monolayers were wounded by scratching 
with a pipette tip along the diameter of the well, and they were washed twice with serum-free 
medium. In order to monitor cell movement into the wounded area, five fields of each wound were 
photographed immediately after the scratch (0 h) and after 24 h [27-28]. The endpoint of the assay 
was measured by calculating the reduction in the width of the wound after 24 h and compared to 0 h 
which is set at 100%. The area of wound healing was calculated by using the ImageJ software [29].  
 
Statistical analysis 
Data were expressed as means ± SD. Significance between experimental groups was determined by 
one-way ANOVA followed by the Bonferroni multiple comparison post-test using GraphPad InStat 
software (San Diego, CA, USA). Values of p≤0.05 were considered statistically significant. 
 
Results 
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Induction of cisplatin resistance  
To analyze the role played by YAP and Nrf2 in CDDP resistance of human bladder cancers, we 
exposed 253J and 253J B-V bladder cancer cells to increasing CDDP concentrations for 12 months. 
Resistance induction was demonstrated by MTT assay and colony forming assay (Supplementary 
data Fig.1). Indeed, the ability to grow, as well as to form colonies, indicated that these cell lines 
were made resistant to cisplatin and thus labeled as 253J C-r and 253J B-V C-r (CDDP-resistant). 
Figure 1 shows the results obtained by the evaluation of GSH/GSSG ratio (Figure 1A), and the 
expression of YAP, Nrf2, and Nrf2 target genes: heme oxygenase 1 (HO-1), thioredoxin (Trx) and 
gluatathione-S-transferase A4 (GSTA4) (Figure 1 B and C). In both cell lines, the acquired 
resistance induced an upregulation of YAP and Nrf2 expressions, accompanied by an increase of 
GSH/GSSG ratio. Accordingly with Nrf2 increase, HO-1 and GSTA4 were upregulated in the 
resistant lines, whereas Trx displayed a different expression and appeared upregulated only in 
resistant 253J cells. In 253J C-r cells the GSH/GSSG ratio was higher than that observed in 253J B-
V C-r cells. Thus, 253J and 253J C-r cells were chosen for the following experiments.  
 
YAP down-regulation sensitized 253J cells to chemotherapeutic agents and reduced Nrf2 
expression. 
To evaluate the role of YAP in CDDP resistance in 253J cells, we modulated its expression and 
examined the response to CDDP treatment. 253J C-r cells were infected with either YAPsh RNAs 
(labeled as YAPsh) or a non-silencing control shRNA (labeled as NSsh) expressing pGIPZ 
lentiviral vector. YAP level in these cells was analyzed by western blot (Fig 2 A) and 
immunofluorescence (Fig. 2 B) confirming that YAP shRNA significantly reduces YAP expression 
in 253J C-r cells. PARP cleavage was used as an indicator of apoptosis induction in a CDDP dose-
response experiment in 253J C-r NSsh and 253J C-r YAPsh cells (Fig. 2 C). YAP knockdown 
makes cancer cells more sensitive not only toward CDDP, but also toward other DNA damage-
inducing agents, such as camptothecin (CPT), doxorubicin (DOX) and gemcitabine (GEM) (Fig. 2 
D). Quantification of cleaved PARP, performed by densitometric scanning and related to the 
representative western blots (Fig. 2 panels C and D) is shown in Fig. 2 panel E.  These results were 
in agreement with previous data obtained in our laboratory on T24 human bladder cancer cells [16]. 
To test the hypothesis of whether YAP has a critical role in controlling the antioxidant potential of 
the cells, we evaluated the GSH/GSSG ratio and Nrf2 expression in 253J C-r NSsh and 253J C-r 
YAPsh cells. In YAP knocked down cells both the GSH/GSSG ratio (Fig. 3A) and Nrf2 protein 
(Fig. 3 B and C) were decreased, indicating that YAP can play a role in the control of this cellular 
antioxidant system.  
10 
 
The reduction of Nrf2 protein expression could depend on the intracellular level of Keap1, which 
binds and drives Nrf2 to proteasomal degradation, or on a reduction of Nrf2 mRNA synthesis. To 
investigate the cause of the reduction of Nrf2 protein expression in YAP knocked down cells, we 
first analyzed Keap1 expression in 253J C-r NSsh and 253J C-r YAPsh (Fig. 3 D). Keap1 
expression was not modified in YAP knocked down 253J C-r cells with respect to the 253J C-r 
NSsh cells, and this suggested that the reduction of Nrf2 protein did not depend on Keap1 targeting. 
On the contrary, the Nrf2 mRNA expression, detected through qRT-PCR varied significantly (Fig. 
3 E). In particular, Nrf2 mRNA expression paralleled with its protein expression, being also higher 
in resistant cells than in sensitive cells, according to the up-regulation of YAP expression, and 
reduced in YAPsh cells with respect to NSsh cells. These results suggested that YAP action on Nrf2 
expression was at the transcriptional level.  
Since previous literature data indicated that YAP-TEAD can modulate FOXM1 expression [22] 
which, in turn, can control Nrf2 expression [21] we analyzed FOXM1 expression in our exclusive 
models (Fig.4 A). Results demonstrated that FOXM1 is upregulated in resistant cells and this 
increase was lost by knocking down YAP in these cells. Moreover, to confirm an involvement of 
FOXM1transcription factor in Nrf2 expression regulation, we silenced FOXM1 through a specific 
siRNA in 253J C-r cells (Fig. 4B) and evaluated the Nrf2 mRNA expression in 253J C-r and in 
253J C-r Nrf2 silenced cells. Results obtained demonstrated that the silencing of FOXM1 reduced 
the expression of Nrf2 mRNA (Fig. 4 C).  
 
Nrf2 silencing reduced YAP expression and sensitized 253J cells to CDDP treatment. 
Since it has been demonstrated that a depletion of antioxidant species can result in a reduction of 
YAP expression [19], we assessed whether the silencing of Nrf2, the master regulator of the 
antioxidant potential, could produce a reduction of YAP expression. To test this hypothesis, 253J C-
r cells were transient silenced for Nrf2 using a specific siRNA. The peak of silencing was reached 
24 hours after siRNA transfection (Fig. 5A). Subsequently, the level of Nrf2 expression gradually 
increased and returned to the control values within 3 days (data not shown). At 24 hours, the 
expression of YAP was reduced in Nrf2 silenced cells with respect to control 253J C-r cells (Fig. 
5B). Immunofluorescence staining confirmed the reduction of YAP protein expression 24 hours 
after siRNA transfection (Fig. 5C). Moreover, we examined the YAP mRNA expression and 
detected a significant reduction in Nrf2 silenced cells (Fig. 5D). It has been reported that the 
oxidation of the Ets family member GABP, which binds to the Yap promoter and activates YAP 
transcription [19], can be inactivated by oxidative mechanisms and by glutathione depletion [19]. 
To confirm that a reduction of cell antioxidant defenses could reduce YAP expression, we analyzed 
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YAP mRNA expression in 253J C-r cells in which GSH was depleted by BSO. Analogously to that 
observed in Nrf2 silenced cells, the BSO treatment reduced the YAP mRNA expression (Fig. 5D). 
To verify whether the silencing of Nrf2 or the BSO treatment could increase the sensitivity toward 
CDDP treatment, the response to a toxic concentration of CDDP was analyzed in 253J C-r and 253J 
C-r Nrf2 silenced cells in terms of crystal violet assay and apoptosis detection through 
cytofluorimetric analysis (Fig. 5 E and F). Results obtained demonstrated that Nrf2 silencing 
significantly reduced cell viability 24, 48 and 72 hours after treatment with 5 µM CDDP and 
increased by about 3 fold the number of apoptotic cells 24 hours after treatment with 20 µg/ml 
CDDP. The reduction of viability in BSO treated cells was similar to that observed in Nrf2 silenced 
cells (Fig. 5 E) 
 
YAP or Nrf2 knocking downs influence the reciprocal expression and sensitize T24 cells to CDDP 
treatment. 
To verify whether a crosstalk between YAP and Nrf2 is also present in another cell line from the 
same origin, we examined the expression of Nrf2 and HO-1 genes in YAP knocked down T24 cells 
(T24 YAPsh) and YAP expression in Nrf2 silenced cells (T24 siNrf2). We previously demonstrated 
that T24 cells display high levels of YAP expression and a high resistance to CDDP treatments, 
which was lost in YAP knocked-down cells (T24 YAPsh) [16]. Results obtained in T24YAPsh cells 
demonstrated that in these cells the Nrf2 expression was decreased, as well as the expression of 
Nrf2 target gene HO-1 (Fig. 6A). According to that observed in 253J C-r YAPsh cells, in T24 
YAPsh cells the GSH/GSSS ratio was reduced (Fig. 6B) and the Nrf2 silencing reduced YAP 
expression (Fig. 6C). Interestingly, in YAPsh cells also silenced for Nrf2, the inhibition of Nrf2 
expression was even more evident (Fig. 6D). Moreover crystal violet assay demonstrated that the 
silencing of YAP and/or Nrf2 expressions or BSO treatment increased the sensitivity to CDDP 
treatment (Fig. 6E).  
 
The down-regulation of both YAP and Nrf2 increased CDDP sensitivity and reduced 253J 
migration. 
The reduction of Nrf2 expression was analyzed in 253J C-r, 253J C-r silenced for Nrf2, 253J C-r 
YAPsh cells and in YAPsh cells silenced for Nrf2. The reduction of Nrf2 expression in YAPsh cells 
silenced for Nrf2 was higher than that observed in Nrf2 silenced cells 48 hour after transfection. 
(Fig. 7A). Concomitant down-regulation of Nrf2 and YAP produced a higher sensitivity toward 
CDDP-induced inhibition of proliferation than that observed after altering one of these proteins at a 
time (Fig. 7B). Moreover, 24 hours after a treatment with 20 µg/ml CDDP, the number of apoptotic 
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cells after the inhibition of both proteins was higher than that observed in single Nrf2 silenced cells 
or in YAP knocked down cells (Fig. 7C).  
A well-established YAP role on physiological cellular behavior, is its action on cell migration 
which is related in oncology field to the invasion and the metastatic capability of tumor cells [30-
32]. In addition, some data indicated that Nrf2 suppression also reduced the migration in different 
tumor cells [33-34]. To verify whether the reduction of YAP and/or Nrf2 expressions could reduce 
cell migration, we analyzed this parameter through the wound healing method in Nrf2 silenced, 
YAP knocked down cells and in cells silenced for both genes (Fig. 8). We observed that 253J 
resistant cells were able to migrate faster than the sensitive ones and that silencing YAP or Nrf2 
reduced the migration of resistant cells. Interestingly, concomitant silencing of YAP and Nrf2 can 
rescue the migration phenotype observed in sensitive cells, indicating that the down-regulation of 
these genes had a synergic effect in the inhibition of cell migration. 
 
Discussion 
The ability of the tumor cells to develop resistance to chemotherapy remains a major challenge in 
the management of urothelial cancer patients. Among the factors involved in chemoresistance, the 
redox adaptation and the increase in detoxifying molecules play an important role in apoptosis 
evasion of chemoresistant cells [35]. GSH is a major player in intracellular redox adaptation and is 
involved in several metabolic pathways, cell cycle progression and antioxidant defenses [36]. Our 
results suggest that the induced resistance to cisplatin in human bladder cancer cells is accompanied 
by an increase of the intracellular level of GSH. Similar results were obtained by Iida et al. which 
demonstrated an increase of gamma-glutamylcysteine synthetase expression and intracellular GSH 
levels in doxorubicin- or cisplatin-resistant human cancer cells compared to sensitive cancer cells 
[37].  
The main enzymes involved in GSH synthesis and utilization are controlled by the transcription 
factor Nrf2 [38]. Consequently, the Nrf2 overexpression is associated with the increase of GSH in 
chemoresistant cells [39]. Our results in bladder cancer cells show a substantial increase in Nrf2 
expression after induction of CDDP resistance. Moreover, we demonstrated that Nrf2 silencing 
resensitized chemotherapy resistant cells to CDDP treatment. It has been reported that Nrf2 induces 
the transcriptional activation of more than 100 detoxification and cytoprotective genes [40], 
including several genes involving in chemoresistance, such as ABCF2 [41], Xct [42], and 
Glutathione S-transferases [43]. Moreover, Nrf2 upregulates the transcription of Bcl-2 and Bcl-xL 
antiapoptotic genes [44, 45], thus Nrf2 down regulation may make cancer cells more prone to 
apoptosis. 
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Recently, YAP role in chemoresistance of several tumors, including bladder cancer, has emerged 
[16]. In our cellular model, the induction of CDDP resistance caused an upregulation of YAP 
expression, and YAP silencing increased the sensitivity of bladder cancer cells not only toward 
CDDP, but also toward other DNA damaging agents, in agreement with our previous observations 
performed in bladder cancers [16]. However, the molecular mechanisms of YAP action, have not 
been completely elucidated. Through TEAD interaction YAP controls a set of genes such as CTGF, 
cyr61, survivin, amphiregulin and AXL [11, 14, 46], and some of them have been associated with 
drug resistance [47]. However, YAP role in controlling the antioxidant defense of chemoresistant 
cancer cells has not yet been reported. Our results suggest that YAP upregulation in chemoresistant 
cells is accompanied by an increase in the GSH/GSSG ratio and Nrf2 expression and, more 
importantly, that YAP knockdown reduced the GSH/GSSG ratio and Nrf2 expression, thus 
indicating a direct contribution of YAP in regulating the antioxidant potential of cancer cells. The 
reduction of the GSH/GSSG ratio and Nrf2 expression have been confirmed in another urothelial 
cell line: T24 cells, which displayed high chemoresistance accompanied by a high level of YAP 
expression [16]. YAP involvement in redox regulation has been reported by Shao et al. in 
cardiomyocytes in which the effect of YAP-FOXO1 interaction and FOXO1-dependent induction 
of anti-oxidant proteins, SOD2 and catalase, counteracted ROS-induced cellular senescence [17]. 
Our results broaden the spectrum of antioxidant activity exerted by YAP, since it could also be 
linked to a regulation of Nrf2 expression, and, consequently, of its target antioxidant genes. The 
demonstration that the YAP-knocking down reduced the Nrf2 mRNA indicated that YAP control on 
Nrf2 expression was at the transcriptional level. Since there was not a direct involvement of YAP in 
the activation of transcription factors which regulated Nrf2 transcription, we postulated an indirect 
action involving FOXM1 transcription factor. The FOXM1 transcription factor plays a crucial role 
in regulating cell proliferation, differentiation, and transformation. Overexpression of FOXM1 is 
associated with a variety of aggressive solid carcinomas, including bladder cancer [12], and it has 
been related to the drug resistance in a variety of cancers [48-50].  
FOXM1 is a downstream target of YAP, which directly induces FOXM1 transcription in a TEAD-
dependent fashion [22]. On the other hand, it has been recently demonstrated that Nrf2 is 
transcriptionally activated by FOXM1 [21]. This observation suggests that YAP may affect Nrf2 
transcription through the regulation of FOXM1 expression. Our results demonstrate that FOXM1 
expression is increased in resistant cells, and that YAP knocking down highly inhibits FOXM1 
protein expression. Moreover, FOXM1 silencing reduced Nrf2 expression, thus suggesting a role 
for FOXM1 in YAP-mediated Nrf2 regulation. 
14 
 
Interestingly, the silencing of Nrf2 also inhibited YAP expression in both 253J C-r and T24 cells, 
suggesting a bidirectional cross-talk between these two molecules. YAP expression inhibition could 
depend on the reduction of Nrf2-controlled antioxidant genes, such as HO-1 and others, with 
consequent oxidation of the Ets family member GABP, which binds to the Yap promoter and 
activates YAP transcription [19]. Indeed, it has been reported that GABP can be inactivated by 
oxidative mechanisms and by glutathione depletion [19], both mechanisms linked to Nrf2 activity. 
The involvement of an oxidative inactivation of GABP in our cell model was also confirmed by the 
observation that YAP mRNA was significantly inhibited in GSH depleted 253J C-r cells after BSO 
treatment. 
Based on these observations, by sustaining the antioxidant potential of the cell, YAP supports its 
expression. In addition, the reduction of antioxidants, by Nrf2 inhibition or BSO treatment, may 
result in GABP inactivation and, consequently, in a YAP expression inhibition. Moreover, the 
silencing of Nrf2 in YAP knocked down cells, resulted in a stronger reduction of Nrf2 expression 
and in an increase of CDDP sensitivity compared to the cells silenced only for Nrf2 or for YAP.  
In addition to the induction of apoptosis, YAP and Nrf2 also control the migration of cancer cells 
[33-34, 51], which contributes to metastatic properties of cancer cells. Our results also show a 
reduction of migration in Nrf2 silenced and YAP knocked down- CDDP-resistant bladder cells and 
a greater inhibitory effect in Nrf2 silenced- YAP knocked down cells.  
 
Conclusions 
Our results suggest that both Nrf2 and YAP are involved in maintaining the antioxidant potential of 
bladder cancer cells and that a bidirectional cross-talk exists between these two jpathway. 
Moreover, we found that the inhibition of both YAP and Nrf2 expression significantly increased the 
CDDP sensitivity, by reducing cell viability, increasing apoptosis induction, and inhibiting the 
migratory capability in chemoresistant bladder cancer cells. These findings provide a rationale for 
targeting these transcriptional regulators in patients with chemoresistant bladder cancer, expressing 
high YAP and antioxidant levels. 
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Figure legendes 
 
Figure 1: Analysis of the GSH/GSSG ratio and Western blot of YAP, Nrf2, HO-1, Trx, 
GSTA4 expressions in wild type and CDDP-resistant cells. A: GSH/GSSG ratio was evaluated 
in wild-type (wt) 253J and 253J B-V cells and after induction of CDDP resistance (253J C-r and 
253J B-V C-r). Values are the mean ± SD of 3 separate evaluations; ** p-value ≤0.01 vs. wild type 
cells. B: Western blot analysis of YAP, Nrf2, HO-1, Trx, and GSTA4 expressions in 253J, 253J C-r, 
253J B-V and 253 J B-V C-r cells. Equal protein loading was confirmed by exposure of the 
membranes to the anti-β-actin antibody. C: Quantification of protein products was performed by 
densitometric scanning. Data were normalized using the β -actin signal and are indicated as the 
mean ± SD from three independent experiments. ** p-value ≤0.01 and * p-value ≤0.05 vs. wild type 
cells. 
 
Figure 2: YAP knockdown and response to chemotherapeutic drugs of YAP-knockdown cells. 
A: 253J C-r cells were infected and stably selected with YAP shRNA (YAPsh) or a non-silencing 
shRNA (NSsh) expressing pGIPZ lentiviral vector. Knockdown confirmation was showed in 
selected cells by western blot analysis. Lower side: densitometric scanning of the bands. Data are 
normalized using the β -actin signal and are indicated as the mean ± SD from three independent 
experiments. ** p-value ≤ 0.01 vs. 253J C-r YAPsh. B: immunofluorescence microscopy of 253J C-
r, 253J NSsh and 253J YAPsh cells stained with anti-YAP antibody and with the secondary 
fluorescein isothiocyanate (FITC)-conjugated antibody. C: Western blot analysis of apoptosis 
markers PARP and cleaved PARP (cl. PARP) in 253J C-r NSsh and 253J C-r YAPsh cells treated 
with 1.5 and 3 µg/ml of CDDP. D: Western blot analysis of apoptosis markers PARP and PARP 
cleavage in 253J C-r NSsh and 253J C-r YAPsh cells treated with 1 and 5µM camptothecin (CPT), 
2 µg/ml of doxorubicin (DOXO) and 2 µM gemcitabine (GEM). α-tubulin served as loading 
control. E: Quantification of cl. PARP performed by densitometric scanning and related to the 
representative western blots showed in Fig 2C and 2D. Data were normalized using the tubulin 
signal and are indicated as the mean ± SD from three independent experiments. * p-value ≤0.05 vs. 
NSsh,  ** p-value ≤0.01 vs. NSsh. 
 
Figure 3: YAP knockdown reduced the GSHGSSG ratio and Nrf2 expression. A: GSH/GSSG 
ratio evaluated in 253J C-r NSsh and 253J C-r YAPsh cells. Values are the mean ± SD of 3 separate 
evaluations. ** p-value ≤0.01 vs. 253J C-r NSsh cells. B: Western blot analysis of Nrf2 expression 
in 253J C-r wild type (wt), 253J C-r YAPsh cells and 253J C-r NSsh. Quantification of protein 
products was performed by densitometric scanning. Data were normalized using the β -actin signal 
and are indicated as the mean ± SD from three independent experiments. ** p-value ≤0.01 vs. 253J 
C-r YAPsh cells. C: immunofluorescence microscopy of 253J C-r, 253J C-r NSsh and 253J C-r 
YAPsh cells stained with anti-Nrf2 antibody and with the secondary fluorescein isothiocyanate 
(FITC)-conjugated antibody. D: Western blot analysis of Keap-1 expression in 253J C-r NSsh and 
253J C-r YAPsh cells; Quantification of protein products was performed by densitometric scanning. 
Data were normalized using the β -actin signal and are indicated as the mean ± SD from three 
independent experiments. E: Quantitative reverse transcription polymerase chain reaction (qRT-
PCR) of Nrf2 mRNA. Abelson (Abl) gene was utilized as housekeeping controls. All analyses were 
carried out in duplicate; results showing a discrepancy greater than one cycle threshold in one of the 
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wells were excluded. The results were analyzed using the ΔΔCt method. ** p-value ≤0.01 vs. 253J 
C-r NSsh cells.  
 
Figure 4. FOXM1 expression in resistant and YAPsh cells and Nrf2 expression in FOXM1 - 
silenced cells. A: Western blot analysis of FOXM1 expression in 253J, 253J C-r NSsh and 253J C-r 
YAPsh cells; lower side: quantification of protein products was performed by densitometric 
scanning (lower side). Data were normalized using the β -actin signal and are indicated as the mean 
± SD from three independent experiments. ** p-value ≤0.01 vs. 253J C-r NSsh cells. B: Western 
blot analysis of FOXM1 expression in 253J C-r (Control, Ctrl), 253J C-r siFOXM1 cells, at 24 and 
48 hours after transfection; lower side: densitometric scanning of bands. Data were normalized 
using the β -actin signal and are indicated as the mean ± SD from three independent experiments. ** 
p-value ≤0.01 vs. untransfected cells. C: Nrf2 mRNA expression in 253J C-r (Control, Ctrl), 253J 
C-r siFOXM1 cells 48 hours after transfection evaluated by quantitative reverse transcription 
polymerase chain reaction (qRT-PCR). Abelson (Abl) gene was utilized as housekeeping controls. 
All analyses were carried out in duplicate; results showing a discrepancy greater than one cycle 
threshold in one of the wells were excluded. The results were analyzed using the ΔΔCt method. * p-
value ≤0.05 vs. 253J C-r NSsh cells.  
 
Figure 5. Nrf2 silencing reduced YAP expression and increased CDDP toxicity. A: Western 
blot analysis of Nrf2 expression in 253J C-r untransfected cells (Control, Ctrl) or 253J C-r cells 
transfected with 50 nM Nrf2-specific siRNA (siNrf2), analyzed 12 and 24 hours after transfection; 
right side: densitometric scanning of bands. Data were normalized using the β -actin signal and are 
indicated as the mean ± SD from three independent experiments. * p-value ≤0.05 and ** p-value 
≤0.01 vs. untransfected cells. B: Western blot analysis of YAP expression in 253J C-r, 253J C-r, 
and siNrf2 cells, at 24 hours after transfection; C: immunofluorescence microscopy of 253J C-r and 
253J C-r Nrf2 siRNA cells stained with anti-YAP antibody and with the secondary fluorescein 
isothiocyanate (FITC)-conjugated antibody. D: YAP mRNA expression in 253J C-r cells silenced 
for Nrf2 and in cells treated with BSO evaluated by quantitative reverse transcription polymerase 
chain reaction (qRT-PCR). Abelson (Abl) gene was utilized as housekeeping controls. All analyses 
were carried out in duplicate; results showing a discrepancy greater than one cycle threshold in one 
of the wells were excluded. The results were analyzed using the ΔΔCt method. ** p-value ≤0.01 vs. 
253J C-r cells. E: Crystal violet assay performed in 253J, 253J C-r, 253J C-r siNrf2 cells and 253J 
C-r cells treated with 200µM BSO, analyzed 24, 48 and 72 hours after the treatment with 5µg/ml of 
CDDP. Results were expressed as percent of control values and are the mean ± SD of 3 separate 
experiments;. ** p-value ≤0.01 vs. 253J C-r cells. F: Cytofluorimetric analysis of apoptosis in 253J 
C-r untreated, and 253J C-r and 253J C-r siNrf2 cells, 24 hours after the treatment with 20 µg/ml of 
CDDP. Results are expressed as percent of annexin V-positive cells and are the mean ± SD from 
three independent experiments. ** p-value ≤0.01 vs. 253J C-r cells, §§ p-value ≤0.01 vs. 253J C-r 
CDDP. 
 
Figure 6: YAP or Nrf2 knocking down influenced the reciprocal expression and sensitized T24 
cells to CDDP treatment. A: Western blot analysis of YAP, Nrf2, HO-1, in T24 NSsh and T24 
YAPsh. Equal protein loading was confirmed by exposure of the membranes to the anti-β-actin 
antibody. Right side: Quantification of protein products performed by densitometric scanning. Data 
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are normalized using GADPH or β -actin signal and are indicated as the mean ± SD from three 
independent experiments. ** p-value ≤0.01 vs. T24 NSsh cells. B: the GSH/GSSG ratio was 
evaluated in T24 NSsh and T24 YAPsh cells. Values are the mean ± SD of 3 separate evaluations; 
** p-value ≤0.01 vs. T24 NSsh cells. C: Western blot analysis of YAP and Nrf2 in T24 wild type 
cells (T24 wt) and T24 wt cells transfected with 50 nM Nrf2-specific siRNA (T24 wt siNrf2). Equal 
protein loading was confirmed by exposure of the membranes to the anti-β-actin antibody. Right 
side: quantification of protein products performed by densitometric scanning. Data were normalized 
using the β -actin signal and are indicated as the mean ± SD from three independent experiments. ** 
p-value ≤0.01 vs. T24 wt cells. D: Western blot analysis of Nrf2 in T24 NSsh and T24 YAPsh cells 
untreated (control, Ctrl) and transfected with 50 nM Nrf2-specific siRNA (siNrf2). Equal protein 
loading was confirmed by exposure of the membranes to the anti-β-actin antibody. Lower side: 
Quantification of protein products performed by densitometric scanning. Data were normalized 
using the β -actin signal and are indicated as the mean ± SD from three independent experiments. ** 
p-value ≤0.01 vs. untreated control cells. E: Crystal violet assay was performed in T24 NSsh, T24 
NSsh siNrf2, T24 NSsh treated with 100 µM BSO (BSO), T24 YAPsh and T24 YAPsh siNrf2 at 
24, 48 and 72 hours after the treatment with 5µg/ml of CDDP. Results were expressed as percent of 
control values and are the mean ± SD of 3 separate experiments. *p-value ≤0.05 and ** p-value 
≤0.01 vs. T24 NSsh; § p-value ≤0.05 and §§ p-value ≤0.01 vs. T24 YAPsh. 
 
Figure 7. The down-regulation of both Nrf2 and YAP increased CDDP toxicity. A: Western 
blot analysis of Nrf2 expression in 253J C-r, 253J C-r siNrf2, 253J C-r YAPsh and 253J C-r 
YAPsh-siNrf2 cells, 48 after transfection; right side: Quantification of protein products performed 
by densitometric scanning. Data were normalized using the β -actin signal and are indicated as the 
mean ± SD from three independent experiments. ** p-value ≤0.01 vs. 253J C-r, §§ p-value ≤0.01 
vs. 253J C-r siNrf2 and ǂ ǂ p-value ≤0.01 vs 253J YAPsh-siNrf2. 
B: Crystal violet assay was performed in 253J C-r NSsh, 253J C-r NSsh siNrf2, 253J C-r YAPsh, 
253J C-r YAPsh siNrf2 cells, at 24, 48 and 72 hours after the treatment with 5µg/ml of CDDP. 
Results were expressed as percent of control values and are the mean ± SD of 3 separate 
experiments. *p-value ≤0.05 and ** p-value ≤0.01 vs. 253J C-r NSsh cells, §p-value ≤0.05 and §§ 
p-value ≤0.01 vs. 253J C-r YAPsh. C: cytofluorimetric analysis of apoptosis in 253J C-r NSsh, 
253J C-r NSsh siNrf2, 253J C-r YAPsh, 253J C-r YAPsh siNrf2 cells, 24 hours after the treatment 
with 20 µg/ml of CDDP. Results are expressed as percent of the control value and are the mean ± 
SD from three independent experiments. ** p-value ≤0.01 vs. 253J C-r NSsh CDDP treated cells, § 
p-value ≤0.05 vs. 253J C-r NSsh-siNrf2 treated with CDDP, ǂ p-value ≤0.05 vs 253J YAPsh treated 
with CDDP. 
 
Figure 8. Migration of 253J cells. Wound healing analysis of the migration of 253J, 253J C-r 
NSsh, 253J C-r NSsh-siNrf2, 253J C-r YAPsh, 253J C-r YAPsh-siNrf2 cells.  
Quantification of wound healing was expressed as percent of cell migration and was measured by 
calculating the reduction in the width of the wound after 24 h and compared to 0 h which is set at 
100%. The data of each assay was done from 3 independent experiments and shown as the 
mean ± SD. ** p-value ≤0.01 vs. 253J C-r NSsh cells, §§ p-value ≤0.01 vs. 253J C-r NSsh-siNrf2, ǂǂ 
p-value ≤0.01 vs 253J YAPsh. 
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